Pharmaceutical Pricing, Reimbursement Environment in ChinaDecision ResourcesNovember 15, 2006 26 Pages - SKU: DECR1378423 |
|
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
5/11/2012 | published by: Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a
|
more...
|
$3,995.00
|
|
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
5/15/2012 | published by: GBI Research
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
Summary
GBI Research, the leading
|
more...
|
$3,500.00
|
|
Out-of-Pocket Healthcare 2012
4/3/2012 | published by: Kalorama Information
Despite numerous attempts to reign in costs of healthcare, consumers are increasingly paying for healthcare products and services from their own monies. The costs of health care products and services continue
|
more...
|
$995.00
|
|
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
3/1/2012 | published by: Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors
|
more...
|
$3,995.00
|
|
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules
4/30/2012 | published by: GBI Research
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules Summary GBI Research, the leading business intelligence provider, has released its latest research
|
more...
|
$3,500.00
|
|
Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation
4/30/2012 | published by: GBI Research
Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation Summary GBI Research, the leading business intelligence provider, has released its latest research “Orphan Disease
|
more...
|
$3,500.00
|
|
Ophthalmic Drugs: World Market Prospects 2012-2022
3/16/2012 | published by: Visiongain
How to find trends and revenue predictions for the ophthalmic drug industry
What are the commercial prospects for treating eye disorders? Visiongain's report shows you potential revenues to 2022 - data, forecasts and discussions.
|
more...
|
$2,642.00
|
|
West and Central Africa Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
BMI View: The better regulated markets of the Gulf Cooperation Council (GCC), South Africa and Israelwill remain the most rewarding and least risky for drugmakers operating in the Middle East and Africa(MEA). However, these markets
|
more...
|
$1,175.00
|
|
China Pharmaceutical Industry Research and Forecast to 2016
3/1/2012 | published by: AM Mindpower Solutions
EXECUTIVE SUMMARY The present report on “China Pharmaceutical Industry Research and Forecast to 2016” analyzes in detail the pharmaceutical industry environment with market sizing in terms of patented drugs, generic drugs, OTC drug and even sub-segments
|
more...
|
$700.00
|
|
Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation
2/29/2012 | published by: GlobalData
Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation Summary The report is an essential source of information and analysis on the KALYDECO (ivacaftor, VX-770) for the treatment of Cystic Fibrosis (CF) patients with
|
more...
|
$500.00
|
Related Markets
Pricing Reports
- Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure
- Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program
- Pricing and Reimbursement of the Healthcare System in India - Low Levels of Drug Reimbursement Lead to a High Out-Of-Pocket Expenditure
- The Royalty Rate Report 2012: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector
- Pharmaceutical Pricing Strategies – Changing Approaches to Meet Challenging Times
